INTRODUCTION
High mobility group box protein 1 (HMGB1) is a ubiquitous nuclear protein that binds and bends DNA and facilitates transcription. HMGB1 can also be released to the extracellular environment, where it mediates inflammation and is implicated in the pathogenesis of many inflammatory diseases. Therapeutic HMGB1 blockade has proven to be beneficial in a number of preclinical models of inflammation, including arthritis, sepsis, transplantation and ischemia (rev. in 1). HMGB1 exerts proinflammatory effects by induction of cytokine production, recruitment and activation of dendritic cells and upregulation of adhesion molecules on endothelial cells (2) . HMGB1 release occurs via active secretion or via leakage from injured cells. A number of cells including monocytes, macrophages, NK cells, dendritic cells, endothelial cells and platelets secrete HMGB1 on stimulation with exogenous or endogenous stimuli (3) (4) (5) (6) , whereas dying cells release HMGB1 passively (7) . Necrotic cells in particular may release high amounts of HMGB1 (8) , which may generate high systemic levels of HMGB1 in patients with sepsis, ischemia, hemorrhagic shock and additional conditions (9) (10) (11) .
Studies on the cytokine-inducing properties of HMGB1 over the past years have
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Noncomplexed HMGB1 has been reported to interact and signal via several cell surface receptor systems. The most studied interactions involve the receptor for advanced glycation end products (RAGE), TLR2 and TLR4. RAGE is a promiscuous receptor stimulated by HMGB1 and additional different ligands. RAGE mediates chemotactic and proliferative activities induced by HMGB1 (8) , whereas it is an unresolved issue whether HMGB1-RAGE signaling may contribute to cytokine synthesis (13, 28) . HMGB1 binding to TLR2 and TLR4 results in nuclear factor (NF)-κB activation in different cell types (29) . Macrophages totally depend on TLR4 for HMGB1-mediated cytokine production, since TLR4-deficient macrophages do not secrete cytokines after HMGB1 exposure (13) . Both TLR4 and TLR2 activation involves an intracellular recruitment of adaptor proteins including myeloid differentiation factor-88 (MyD88) and TIR domaincontaining adaptor protein (TIRAP; also termed MAL), which activates signaling cascades, ultimately leading to NF-κB and mitogen-activated protein kinase (MAPK) activation and thereby production of cytokines and other inflammatory molecules. Alternatively, TLR4 may induce cytokine and IFN type 1 synthesis via recruitment of the TIR domain-containing adaptor-inducing IFN-β (TRIF; also termed TICAM-1) and TRIF-related adaptor molecule (TRAM; also termed TICAM-2) (30).
Besides its proinflammatory role, HMGB1 also promotes tissue regeneration, for example, by inducing proliferation and migration of stem cells. These functions are mainly reported to be mediated through RAGE. Thus, to better understand the proinflammatory features of HMGB1 and of HMGB1-partner molecule complexes, it is pivotal to understand which receptors and signaling pathways are involved in and activated by HMGB1 and HMGB1-partner molecule complex stimulation, respectively. Such knowledge also has bearing for the design of therapies targeting the proinflammatory function of HMGB1 in different inflammatory conditions. Whereas many studies have addressed the receptor usage of purified or recombinant HMGB1, little is known about the engagement of receptors recognizing HMGB1-partner molecule complexes, the subsequent intracellular signal transduction pathways and the molecular mechanisms underlying the potentiating features of HMGB1-partner molecule complexes. The present study was aimed at resolving this unsolved issue and to test our hypothesis that one of the HMGB1 receptors (RAGE, TLR2 or TLR4) might function as a coreceptor in a hetero meric, signaling receptor complex and contribute to the enhancing effects of HMGB1 complexes.
MATERIALS AND METHODS

Reagents
Tag-free recombinant rat HMGB1 free of endotoxin was purchased from HMGBiotech (Milan, Italy). Pam 3 CSK 4 was obtained from InvivoGen (San Diego, CA, USA). Dulbecco's modified Eagle's medium (DMEM), Opti-MEM ® , phosphate-buffered saline (PBS), penicillin, streptomycin, HEPES, sodium pyruvate and β-mercaptoethanol were from Invitrogen (Carlsbad, CA, USA). LPS extracted from Escherichia coli O55:B5 and purified by ion exchange, as well as fetal calf serum, was purchased from Sigma-Aldrich (St. Louis, MO, USA). Heparin (5,000 international units (IU/ mL) was from LEO Pharma A/S (Ballerup, Denmark).
Preparation of Recombinant HMGB1
Recombinant rat HMGB1 with a calmodulin-binding protein tag was expressed in E. coli strain BL21 (for sequence, see Wang et al. [3] ). The preparation was first run through a calmodulin affinity column (Calmodulin Sepharose 4B; GE Healthcare, Chalfont St. Giles, U.K.), and the eluate was then further purified with ion exchange chromatography (MonoS 5/50 GL column; GE Healthcare). Protein was stored at -80°C in a buffer containing 50 mmol/L Tris, 4 mmol/L EGTA, 200 mmol/L NaCl and 2.5 mmol/L DTT at pH 8.0. A Toxin Eraser Kit (GenScript, Piscataway, NJ, USA) was used for removal of endotox-ins, resulting in endotoxin levels below 6 endotoxin units (EU)/mg protein, as measured by Limulus assay.
Mice
All animal procedures were approved by the Stockholm North Ethical Committee in Sweden. RAGE -/-mice were provided by Bernd Arnold and Angelika Bierhaus (German Cancer Research Center, Heidelberg, Germany) and
TLR2
-/-and TLR4 -/-mice by S Akira (Osaka University, Osaka, Japan). All knockout mice were on a C57Bl/6 background. Wild-type C57Bl/6 mice were purchased from Charles River Laboratories (Wilmington, MA, USA). Animals were kept and bred at the Karolinska Institutet animal facility in a specific pathogen-free environment with standard temperature and a 12-h light/dark cycle. Animals had free access to water and standard rodent chow. Female mice were used in all experiments.
Harvest and Culture of Mouse Peritoneal Macrophages
Wild-type or knockout mice were euthanized by CO 2 asphyxiation, and peritoneal macrophages were harvested by lavage of the peritoneal cavity with 5 mL DMEM supplemented with 10% fetal calf serum, 100 units/mL penicillin, 100 μg/mL streptomycin, 10 mmol/L HEPES, 1 mmol/L sodium pyruvate, 50 μmol/L β-mercaptoethanol and 10 IU/mL heparin.
Cells were pelleted by centrifugation at 200g at 4°C for 7 min and resuspended in new medium without heparin. Cells were plated at 100,000 cells per well in a 96-well plate (Sarstedt, Nümbrecht, Germany) and allowed to rest overnight. The next day, the cells were washed to remove nonadherent cells and the medium was changed to OPTIMEM supplemented with penicillin, streptomycin, HEPES, sodium pyruvate and β-mercaptoethanol. Cells were then stimulated for [17] [18] [19] [20] 
Preparation of HMGB1 Complexes
HMGB1 in PBS, either purchased from HMGBiotech or produced in our laboratory, was mixed together with LPS or Pam 3 CSK 4 in polypropylen tubes in different ratios to give final concentrations in cell cultures, as indicated in the figures. HMGB1 from both sources showed the same stimulatory patterns, both alone and in complexes, and we therefore chose not to distinguish them in the text and figures. The stimulatory ability of the complexes depends on both the temperature and the length of time in which they are formed (14; personal communication, P. Lundback). For these studies, the mixtures were standardly incubated at 4°C for 16 h before addition to cell cultures. Verification of complex formation between HMGB1 and LPS has been demonstrated previously by us and others (14, 18) .
Cytokine Analysis
IL-6 levels were measured in the supernatants by enzyme-linked immunosorbent assay using hIL-6 DuoSet kits from R&D Systems (Minneapolis, MN, USA) and following the manufacturer's instructions (detection limit: 15.6 pg/mL).
Statistical Analysis
Cytokine production in peritoneal macrophage culture after stimulation with HMGB1 complexes was assumed to follow Gaussian distribution. A twotailed Student t test was used to calculate statistical significance between different genotypes. One sample t test was used to calculate statistical significance within groups with the hypothetical value set to 1, corresponding to the LPS/Pam 3 CSK 4 10 ng/mL bar ( Figures 1C, D) . A P value <0.05 was considered to be statistically significant. Statistical analyses were performed using GraphPad Prism version 5.01 for Windows (GraphPad Software, San Diego, CA, USA).
RESULTS
HMGB1 Complexes with TLR Ligands Signal via the Reciprocal TLR of the Partner Ligand
We have previously shown that batches of HMGB1 that induce cell migration but not cytokine production may form complexes with exogenous or endogenous proinflammatory molecules, resulting in strongly enhanced cytokine production compared with the partner ligand alone (14) . To elucidate mechanisms mediating this unexplained synergy, we used cultured peritoneal macrophages from mice deficient of RAGE, TLR2 or TLR4 receptors, respectively, and stimulated the cells with HMGB1 complexes or with nonstimulatory HMGB1 alone.
HMGB1 in complex with low amounts of the TLR4 ligand LPS induced significantly enhanced IL-6 production in wildtype cells, compared with stimulation with the individual components alone ( Figures 1A, C) . These results are in line with our previously published data (14) . RAGE -/-and TLR2 -/-cells responded equally as well as the wild-type cells to stimulation ( Figures 1A, C) . In contrast, a lack of TLR4 expression completely abolished the IL-6 production induced by HMGB1-LPS complexes or by LPS alone ( Figure 1A) . Stimulation with HMGB1 in complex with a low dose of the synthetic TLR2 ligand Pam 3 CSK 4 generated synergistically increased IL-6 production compared with stimulation with HMGB1 or Pam 3 CSK 4 alone (Figures 1B, D) . Cellular depletion of RAGE or TLR4 did not reduce the IL-6 production induced by the HMGB1 complex or by Pam 3 CSK 4 alone compared with that in wild-type macro phages (Figures 1B, D) 
Synergistic Effect by HMGB1 Is a Result of Quantitative Rather than Qualitative Changes in Intracellular Signal Pathways
We next asked whether the synergistic enhancement of cytokine production induced by HMGB1 complexes could be a minimal amounts of IL-6 in response to these stimulations, indicating the importance of these adaptor molecules for the signaling of LPS and HMGB1-LPS complexes. When data were normalized to 1 μg/mL LPS, no significant differences were recorded between the different genotypes regarding the relative amounts of IL-6 produced in response to HMGB1-LPS complexes or LPS alone ( Figure 3A ). This result demonstrates that deficiency of any of the studied adaptor molecules had similar effects on HMGB1-LPS complex stimulation compared with activation with LPS only. MyD88 -/-and TIRAP -/-cells expressed equivalent viability and produced comparable amounts of nitric oxide in response to IFN-γ and tumor necrosis factor stimulation as the other genotypes (data not shown), demonstrating that the cells were functional and had the capacity to produce inflammatory mediators in response to stimulation. MyD88 was demonstrated to be an absolute requirement for IL-6 production in response to Pam 3 CSK 4 or HMGB1-Pam 3 CSK 4 complex stimulation, since MyD88 gene deletion totally prevented macrophage activation (Figure 2B) . Gene deficiencies for TIRAP, TRIF or TRAM did not influence the rel- cultures demonstrating substantial TLR2-mediated IL-6 production might be explained by the previous demonstration that TIRAP is dispensable in TLR2 signaling at high TLR2 ligand concentrations in macro phage cultures. TLR4 requires the presence of TIRAP to recruit MyD88, where as TLR2 may dimerize with TLR1 or TLR6 to allow TIRAP-independent recruitment of MyD88 (31) . In summary, although deficiency of the TLR adaptor molecules had quantitative effects in IL-6 production after stimulation with HMGB1 complexes, there were no qualitative effects on the synergistic ability of the HMGB1 complexes when compared with ligand stimulation alone.
DISCUSSION
The common denominator of the experiments with HMGB1-LPS complexes and HMGB1-Pam 3 CSK 4 complexes is that the activity of the complexes relies on engaging the identical cell surface receptors and intracellular adaptor proteins as required for the function of the noncomplexed TLR ligand. No evidence could be demonstrated that the mechanism behind the synergistic effect of HMGB1-TLR ligand complexes is through usage of RAGE, TLR2 or TLR4 as coreceptors. The TLR4 ligand LPS and the HMGB1-LPS complexes signaled via TLR4 without any requirement for TLR2 or RAGE in- Figure 2B ).
CONCLUSION
We and other groups have previously established that cytokine production in macrophages stimulated by highly purified, noncomplexed HMGB1 is a totally TLR4-dependent process (13) . HMGB1 binds to the TLR4 signaling complex through a mechanism that requires cysteine in position 106 of the HMGB1 molecule to be in the reduced form, expressing a thiol group (13, 33) . Oxidation of this critical cysteine or exposure of the HMGB1 molecule to dithiothreitol (DTT) denatures the HMGB1-TLR4 interactions and prevents cytokine induction (13, 17, 33) . The present HMGB1-TLR ligand complex experiments were performed with HMGB1 batches exposed to DTT, and they did not bind to TLR4, as revealed by surface plasmon resonance analysis (data not shown). We deliberately designed the experiments to be based on studies of batches of HMGB1 unable to induce cytokines to mimic situations in vivo with non-TLR4-binding forms of HMGB1. Oxidation represents another modification by which HMGB1 is prevented from being able to bind to TLR4, illustrated by the fact that HMGB1 is converted from a proinflammatory to a tolerogenic molecule by oxidation during the apoptotic program of a cell (17) . Exposure to oxidative bursts during inflammation will also block HMGB1-TLR4 interactions. The results of our in vitro experiments support the hypothesis that, in an in vivo situation, a pacified version of HMGB1 unable to interact with TLR4 is still capable of promoting and enhancing inflammation by complex formation when present in an environment with microbial TLR ligands. One question not addressed in this study 
